Drug Free Solution Stock Performance
| DSOL Stock | USD 0 0.00 0.00% |
The firm shows a Beta (market volatility) of -1.76, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Drug Free are expected to decrease by larger amounts. On the other hand, during market turmoil, Drug Free is expected to outperform it. Drug Free Solution right now shows a risk of 0.0%. Please confirm Drug Free Solution treynor ratio and day median price , to decide if Drug Free Solution will be following its price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Drug Free Solution has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent basic indicators, Drug Free is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors. ...more
Drug |
Drug Free Relative Risk vs. Return Landscape
If you would invest 0.11 in Drug Free Solution on September 27, 2025 and sell it today you would earn a total of 0.00 from holding Drug Free Solution or generate 0.0% return on investment over 90 days. Drug Free Solution is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Drug, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Drug Free Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Drug Free's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Drug Free Solution, and traders can use it to determine the average amount a Drug Free's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| DSOL |
Based on monthly moving average Drug Free is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Drug Free by adding Drug Free to a well-diversified portfolio.
Drug Free Fundamentals Growth
Drug Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Drug Free, and Drug Free fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Drug Pink Sheet performance.
| Return On Asset | -12.7 | |||
| Operating Margin | (413.00) % | |||
| Current Valuation | 496.08 K | |||
| Shares Outstanding | 35.94 M | |||
| Price To Earning | (1.56) X | |||
| Price To Sales | 239.51 X | |||
| EBITDA | (862.83 K) | |||
| Cash And Equivalents | 7.12 K | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (692.31 K) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 11.79 K | |||
| Retained Earnings | (1.68 M) | |||
| Current Asset | 7 K | |||
| Current Liabilities | 391 K | |||
About Drug Free Performance
By examining Drug Free's fundamental ratios, stakeholders can obtain critical insights into Drug Free's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Drug Free is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Drug Free Solution, Inc., a lifestyle company, delivers proprietary emotional wellness technology, known as Living Breath Process. The company was formerly known as Living Breath Project, Inc. and changed its name to Drug Free Solution, Inc. in January 2014. DRUG FREE is traded on PNK Exchange in the United States.Things to note about Drug Free Solution performance evaluation
Checking the ongoing alerts about Drug Free for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Drug Free Solution help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Drug Free Solution generated a negative expected return over the last 90 days | |
| Drug Free Solution has some characteristics of a very speculative penny stock | |
| The company has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Drug Free until it has trouble settling it off, either with new capital or with free cash flow. So, Drug Free's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Drug Free Solution sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Drug to invest in growth at high rates of return. When we think about Drug Free's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (755.87 K) with loss before overhead, payroll, taxes, and interest of (171.22 K). | |
| Drug Free Solution currently holds about 7.12 K in cash with (692.31 K) of positive cash flow from operations. |
- Analyzing Drug Free's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Drug Free's stock is overvalued or undervalued compared to its peers.
- Examining Drug Free's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Drug Free's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Drug Free's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Drug Free's pink sheet. These opinions can provide insight into Drug Free's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Drug Pink Sheet
Drug Free financial ratios help investors to determine whether Drug Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Drug with respect to the benefits of owning Drug Free security.